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Abstract
Background Our aim was to demonstrate that, despite
advances in treatment and surveillance of node-positive
cutaneous melanoma, rates of overall survival (OS) and
melanoma-speciﬁc survival (MSS) have not changed over
the last two decades.
Methods We used the Surveillance, Epidemiology, and
End Results (SEER) database of the National Cancer
Institute to identify patients with node-positive cutaneous
melanoma. Patients were categorized by treatment era; the
ﬁrst era encompassed patients diagnosed from 1988 to
1999 and the second era 2000 to 2006. Multivariate Cox
proportional hazards models compared rates of OS and
MSS between treatment eras while controlling for known
prognostic factors. We reported risks of death as hazard
ratios (HR) with 95% conﬁdence intervals (CI) and set
signiﬁcance at P B 0.05.
Results Entrance criteria were met by 6,868 patients,
1,631 (23.8%) treated in era I and 5,237 (76.3%) treated in
era II. On multivariate analysis, era II patients did not
demonstrate a signiﬁcantly different risk of death from any
cause (HR 0.89, CI 0.79–1.01; P\0.08), but they did have
a lower risk of melanoma-speciﬁc mortality (HR 0.81, CI
0.71–0.93; P = 0.003) relative to their era I counterparts.
Conclusions Over nearly two decades, MSS but not OS
has improved for AJCC stage III melanoma patients. Stage
migration is likely responsible for any improvement in
MSS among patients in the most recently diagnosed era.
Introduction
Lymph node status remains the dominant prognostic factor
for cutaneous melanoma. Current American Joint Com-
mittee on Cancer (AJCC)/International Union against
Cancer (UICC) staging reﬂects the heterogeneous nature of
lymph node positive melanoma. Patients are categorized
according to the number and volume of lymph nodes
involved as stage IIIA, IIIB, or IIIC. While the average
5-year overall survival (OS) rate for stage III melanoma
patients is approximately 45%, the survival rates for IIIA,
IIIB, and IIIC disease are 67, 53, and 26%, respectively [1].
These survival rates are quite dramatic in comparison to
those experienced by patients without lymph node metas-
tases. Patients with localized AJCC stage I and II mela-
noma have 10-year survival rates approximating 85 and
55%, respectively [1].
The chasm between survival rates in patients with
localized and regionally metastatic disease has, over the last
two decades, motivated the development of new approaches
for the management of patients with lymph node metasta-
ses. Advances in the ﬁelds of medical oncology, surgery,
radiology, and radiation oncology have been well docu-
mented, many with inﬂuence on OS and melanoma-speciﬁc
survival (MSS). Nonspeciﬁc immunotherapy has demon-
strated signiﬁcant improvement in recurrence-free survival
with the administration of high-dose interferon a-2b (IFN
a-2b) in stage III melanoma patients [2–6]. Although OS
was not the primary study endpoint, OS beneﬁts were seen
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melanoma has included the use of therapeutic lymph node
dissection, elective lymph node dissection, and, most
recently, lymphatic mapping/sentinel lymph node biopsy
(LM/SNB) with or without completion lymph node dis-
section, as indicated by the pathologic status of the sentinel
node [7–9]. Improved patient outcomes resulting from
advances in disease staging attributed to imaging technol-
ogy such as computed tomography (CT), magnetic reso-
nance imaging (MRI), and positron emission tomography
(PET) are admittedly limited. Studies investigating the
contribution of CT and MRI indicate that approximately 7%
of asymptomatic patients are diagnosed with unsuspected
disease that went undetected in previous imaging studies
[10–12]. At the time of diagnosis, the majority of patients
with AJCC stage III melanoma will not demonstrate evi-
dence of advanced disease on imaging studies [13, 14].
Finally, the development of conformal techniques of radi-
ation delivery has decreased the morbidity of external beam
radiotherapy, and in select clinical situations, application of
radiation therapy in addition to surgery decreases local
recurrence rates and may improve MSS [15–20]. Despite
these advances, lymph node metastases continue to portend
a poor prognosis.
We hypothesized that advances in melanoma treatment
during the last 20 years have been insufﬁcient to inﬂuence
rates of OS and MSS. To test this hypothesis, we used a
national, population-based database.
Patients and methods
The Surveillance, Epidemiology, and End Results (SEER)
database of the National Cancer Institute was used to
identify all patients with lymph node positive (AJCC stage
III) cutaneous melanoma diagnosed from 1988 to 2006.
SEER collects cancer incidence and survival data from 17
population-based cancer registries representing 26% of the
U.S. population. Current SEER registries consist of: the
states of Connecticut, Hawaii, Iowa, Kentucky, Louisiana,
New Jersey, New Mexico, and Utah; the metropolitan areas
of Atlanta, Detroit, San Francisco-Oakland, Seattle-Puget
Sound, and San Jose-Monterey; and the Alaska Native
Tumor Registry, rural Georgia, Greater California, and Los
Angeles County. SEER registries routinely collect data on
patient demographics, primary tumor site, tumor mor-
phology, stage at diagnosis, and ﬁrst course of treatment.
All cases of primary, histologically conﬁrmed, cutane-
ous melanoma with lymph node metastasis were eligible
for the study. We restricted eligibility to patients diagnosed
between 1988 and 2006. Patients with distant metastases at
the time of diagnosis were excluded. Finally, we excluded
cases identiﬁed by death certiﬁcate or autopsy and cases
with missing cause of death. The ﬁnal sample included
6,868 patients.
Patients were divided into two treatment eras:
1988–1999 (era I) and 2000–2006 (era II). Comparisons of
patients treated during the two eras were performed with the
chi-square test. We compared univariate rates of OS and
MSS according to treatment era with the Kaplan–Meier
method. Additional survival comparisons were made for the
following patient, tumor, and treatment-speciﬁc factors: age
at diagnosis (using the median split method for age B55 vs.
[55 years), sex, Breslow depth (0, B1, 1.01–2, 2.01–4,
[4 mm, unknown), number of metastatic lymph nodes
(1, 2–3, C4), presence of ulceration (non-ulcerated, ulcer-
ated), and type of primary surgery (amputation, tumor abla-
tion, local excision, wide excision with 1–2 cm margins,
wide excision with [2 cm margins, none, unknown). Dif-
ferencesbetween oramongsurvivalcurveswereassessedvia
the log-rank test. Date and cause of death were available via
database linkage to death certiﬁcate data. Survival time was
calculated as the number of completed months between the
date of diagnosis and whichever occurred ﬁrst: date of death,
date last known to be alive, or December 31, 2006. The
endpoints for the present study were OS and MSS. Patients
whowerelosttofollow-uporsurvivedbeyondDecember31,
2006, were coded as censored observations.
The proportional hazards model was conﬁrmed graphi-
cally using the ‘‘stphtest’’ from STATA, version 10 (Stata-
Corp, College Station, TX). We used Cox proportional
hazards models to assess the effect of treatment era on OS
and MSS, while adjusting for factors found to be signiﬁcant
on univariate analysis. Risks of overall and melanoma-
speciﬁc mortality were reported as HR with 95% CI; sig-
niﬁcance was set at P B 0.05. All statistical analyses were
two-tailed and were performed with STATA, version 10.
Results
A cohort of 6,868 patients with lymph node metastasis posi-
tive (AJCC stage III) cutaneous melanoma met study entry
criteria. Of these, 1,631 (23.8%) were treated during era I
(1988–1999) and 5,237 (76.3%) were treated during era II
(2000–2006). Characteristics of the study population, based
ontreatmentera,are presentedinTable 1.Brieﬂy,signiﬁcant
differences were noted between patients treated during era I
and era II with respect to patient age, primary tumor Breslow
depth,ulceration,numberoflymphnodemetastases,andtype
of primary surgery (all P\0.001). Of note, data regarding
Breslow depth were unknown for 20.5% of era I patients and
10.9% of era II patients. Type of primary surgery was
unknownfor68.9%oferaIpatientsand29%oferaIIpatients.
The number of lymph node metastases was unknown for 8.2
and 2.4% of era I and era II patients, respectively.
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123Median OS and MSS were 65 and 124 months,
respectively, for the study population as a whole. Rates of
5-year OS and MSS were 51 and 59%, respectively.
Median OS was 47 months for patients treated during era I
and 70 months for those treated during era II. Median MSS
was 64 months for patients treated during era I and not yet
achieved for those treated during era II. Rates of 5-year OS
were 45 and 54% for era I and II patients, respectively.
Five-year MSS rates were 51% for era I patients and 62%
for era II patients.
Univariate analysis of OS and MSS demonstrated all
factors as signiﬁcant predictors of OS and MSS (age, sex,
Breslow depth, tumor ulceration, number of lymph node
metastases, and type of surgery; all P\0.001. Speciﬁ-
cally, treatment era was a signiﬁcant predictor of both OS
(Fig. 1) and MSS (Fig. 2) on univariate analysis.
Multivariate models were created for both OS and MSS
(Table 2). Increasing age (HR 1.03, CI 1.02–1.03;
P\0.001), Breslow depth of 2.01–4 mm (HR 1.52, CI
1.33–1.72; P\0.001), Breslow depth unknown (HR 1.19,
CI 1.03–1.37; P = 0.017), primary tumor ulceration (HR
1.29, CI 1.18–1.41; P\0.001), and increasing number of
nodal metastases (2–3 metastases: HR 1.46, CI 1.33–1.59;
P\0.001; C4 metastases: HR 2.54, CI 2.28–2.83,
P\0.001; unknown number of metastases: HR 2.10, CI
1.79–2.47; P\0.001) were predictive of an increased risk
of death from any cause. Female sex (HR 0.79, CI
0.73–0.86; P\0.001) and Breslow depth B1m m ( H R
0.84, CI 0.73–0.96; P = 0.01) both predicted a decreased
risk of death from any cause. Of note, in contrast to uni-
variate analysis ﬁndings, patients treated during era II did
not differ in risk of death relative to their era I counterparts
(HR 0.89, CI 0.78–1.01; P = 0.065).
Increasing age similarly predicted an increased risk of
melanoma-speciﬁc mortality (HR 1.02, CI 1.02–1.02;
P\0.001). Additional factors predicting a decreased risk
Table 1 Patient, tumor, and treatment-speciﬁc factors according to
treatment era
Variable Era I: 1988–1999
(n = 1,631)
Era II: 2000–2006
(n = 5,237)
P value
Age, years
B56 910 2,592 \0.001
[56 721 2,645
Sex
Male 1,045 3,324 =0.66
Female 586 1,913
Breslow depth, mm
0 38 109 \0.001
B1 233 897
1.01–2 299 1,261
2.01–4 411 1,327
[4 315 1,072
Unknown 335 571
Ulceration
Absent 1,378 3,682 \0.001
Present 253 1555
Number of lymph node metastases
1 886 3,225 \0.001
2–3 377 1,355
C4 234 532
Unknown 134 125
Surgery
Amputation 2 89 \0.001
Ablation 1 2
Local excision 50 1054
Wide excision
(1–2 cm)
427 3,555
Wide excision
([2 cm)
0 264
None 27 246
Unknown 1,124 29
Fig. 1 Kaplan–Meier curves of overall survival comparing patients
treated during era I (1988–1999) with those treated in era II
(2000–2006)
Fig. 2 Kaplan–Meier curves of melanoma-speciﬁc survival compar-
ing patients treated during era I (1988–1999) and era II (2000–2006)
World J Surg (2011) 35:1567–1572 1569
123of melanoma-speciﬁc mortality included Breslow depth of
1.01–2 mm (HR 1.16, CI 1.01–1.34; P = 0.038), Breslow
depth of 2.01–4 mm (HR 1.61, CI 1.39–1.87; P\0.001),
Breslow depth unknown (HR 1.29, CI 1.10–1.51;
P = 0.002), primary tumor ulceration (HR 1.32, CI
1.19–1.47; P\0.001), and increasing number of nodal
metastases (2–3 metastases: HR 1.51, CI 1.36–1.67;
P\0.001; C4 metastases: HR 2.71, CI 2.41–3.06;
P\0.001; unknown number of metastases: HR 2.20, CI
1.84–2.64; P\0.001). A decreased risk of death from
melanoma was noted for female sex (HR 0.80, CI
0.73–0.88; P\0.001), Breslow depth B1 mm (HR 0.83,
CI 0.71–0.97; P = 0.023), no primary surgery (HR 0.86,
CI 0.75–0.99; P = 0.035), unknown type of primary sur-
gery (HR 0.68, CI 0.49–0.96; P = 0.028), and treatment
during era II (HR 0.81, CI 0.70–0.93; P = 0.003). Patients
treated during era II experienced a 19% decreased risk of
death due to melanoma relative to their era I counterparts.
Discussion
We hypothesized that the advances in AJCC stage III
melanoma treatment have not led to improvements in OS
Table 2 Multivariate Cox proportional hazards models of overall
survival and melanoma-speciﬁc survival
Hazard
ratio
95% conﬁdence
interval
P value
Overall survival
Age 1.03 1.02–1.03 \0.001*
Sex
Male (referent) (referent) (referent) (referent)
Female 0.79 0.73–0.86 \0.001*
Breslow depth, mm
0 mm (referent) (referent) (referent) (referent)
B1 mm 0.84 0.73–0.96 =0.01*
1.01–2 mm 1.10 0.97–1.25 =0.148
2.01–4 mm 1.52 1.33–1.72 \0.001*
[4 mm 0.88 0.63–1.24 =0.457
Unknown 1.19 1.03–1.37 =0.017*
Ulceration
Absent (referent) (referent) (referent) (referent)
Present 1.29 1.18–1.41 \0.001*
Number of lymph Node metastases
1 (referent) (referent) (referent) (referent)
2–3 1.46 1.33–1.59 \0.001*
C4 2.54 2.28–2.83 \0.001*
Unknown 2.10 1.79–2.47 \0.001*
Type of surgery
Local excision
(referent)
(referent) (referent) (referent)
Amputation 2.58 0.64–10.39 =0.182
Ablation 1.11 0.81–1.52 =0.531
Wide excision
(1–2 cm)
1.07 0.83–1.38 =0.60
Wide excision
([2 cm)
1.09 0.92–1.30 =0.317
None 0.90 0.79–1.02 =0.094
Unknown 0.78 0.59–1.04 =0.096
Era
Era I (referent) (referent) (referent) (referent)
Era II 0.89 0.78–1.01 =0.065
Melanoma-speciﬁc survival
Age 1.02 1.02–1.02 \0.001*
Sex
Male (referent) (referent) (referent) (referent)
Female 0.80 0.73–0.88 \0.001*
Breslow depth, mm
0 mm (referent) (referent) (referent) (referent)
B1 mm 0.83 0.71–0.97 =0.023*
1.01–2 mm 1.16 1.01–1.34 =0.038*
2.01–4 mm 1.61 1.39–1.87 \0.001*
[4 mm 0.91 0.62–1.33 =0.646
Unknown 1.29 1.10–1.51 =0.002*
Table 2 continued
Hazard
ratio
95% conﬁdence
interval
P value
Ulceration
Absent (referent) (referent) (referent) (referent)
Present 1.32 1.19–1.47 \0.001*
Number of lymph node metastases
1 (referent) (referent) (referent) (referent)
2–3 1.51 1.36–1.67 \0.001*
C4 2.71 2.41–3.06 \0.001*
Unknown 2.20 1.84–2.64 \0.001*
Type of surgery
Local excision
(referent)
(referent) (referent) (referent)
Amputation NA NA NA
Ablation 1.18 0.84–1.68 =0.34
Wide excision
(1–2 cm)
1.06 0.80–1.41 =0.67
Wide excision
([2 cm)
1.04 0.86–1.26 =0.713
None 0.86 0.75–0.99 =0.035*
Unknown 0.68 0.49–0.96 =0.028*
Era
Era I (referent) (referent) (referent) (referent)
Era II 0.81 0.70–0.93 =0.003*
* Indicates statistical signiﬁcance (P B 0.05)
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123and MSS. We used the SEER database and categorized
patients into remote (era I, 1988–1999) and current (era II,
2000–2006) eras. Our ﬁndings indicate that MSS, but not
OS, was improved for patients treated during era II.
There are several potential explanations for this ﬁnding.
The MSS beneﬁt demonstrated by patients in era II may be
due to stage migration. Because the ﬁrst randomized con-
trolled data demonstrating the accuracy of LM/SNB were
not published until 1999 [21], era II patients were more
likely than era I patients to have undergone a LM/SNB
procedure for regional lymph node staging. LM/SNB is
well established as the standard means of evaluating the
regional nodal basin of localized melanoma [22, 23].
Because the sentinel node represents the most likely site of
tumor metastasis in the regional lymphatic basin, focused
pathologic examination of the sentinel node has become a
useful method of ultrastaging the regional nodes [21, 24,
25]. Microscopic tumor burden was not routinely detect-
able prior to identiﬁcation and detailed analysis of the
sentinel node. Patients from era I with microscopic regional
disease in their lymph node dissection specimen would not
have easily been detected by an unfocused pathology exam
in which nodes were traditionally only bivalved. As a
result, a proportion of patients in the era I prior to devel-
opment of LM/SNB would likely have been diagnosed as
stage II [26], whereas those in era II would be diagnosed as
stage III. Because LM/SNB was not routinely available
during the majority of era I, nodal metastases would likely
have been diagnosed at a more advanced stage in patients
from this era. Balch et al. demonstrated that nodal tumor
burden matters; 5-year survival for stage III melanoma
patients with lymph node micrometastases was 67%, but it
was 43% for those with macrometastases in a population of
2,313 patients diagnosed and treated in the contemporary
era [27]. In this regard, our ﬁndings are consistent with
those of the ﬁrst Multicenter Sentinel Lymphadenectomy
Trial (MSLT-I), which randomized patients with interme-
diate-thickness melanomas to wide excision alone or wide
excision plus LM/SNB and completion lymphadenectomy
in cases of sentinel node metastasis [25]. This trial con-
cluded that there was no MSS beneﬁt to LM/SNB. How-
ever, when comparing the population at risk, namely those
patients who ultimately developed nodal metastases in the
wide excision group and those patients with sentinel node
metastases in the comparison group, there was a clear
beneﬁt to LM/SNB in terms of MSS. Indeed, this is exactly
what we appreciated in our study. While we do not have
data regarding the indications for lymphadenectomies in
era 1 and era 2 patients, we have shown that those patients
more likely to receive LM/SNB (i.e., those diagnosed and
treated after 1999) demonstrated a survival advantage.
Our study was subject to limitations. We excluded cases
of stage III melanoma prior to 1988, primarily because
cases from these years had incomplete data regarding the
number of lymph node metastases that would have made
multivariate comparisons prohibitive. Furthermore, while
we have good information regarding the type of treatment
patients received (surgery, radiation, or both), we do not
have data on the appropriateness or adequacy of that
treatment for individual patients. It is unlikely, given our
sample size, for such deﬁciencies to play a signiﬁcant role
in our results. Perhaps most signiﬁcantly, we have no
information regarding whether patients received chemo-
therapy, immunotherapy, biotherapy, or any other adjuvant
medical treatment with the exception of radiation therapy,
as SEER does not collect these data. Because IFN a-2b has
demonstrated recurrence free and OS beneﬁts [2–6], and
because use of IFN a-2b has taken place almost entirely
within era II, it is also possible that this may have inﬂu-
enced our results. SEER also does not provide important
information regarding patients’ past medical history or
co-morbidities that may inﬂuence OS outcomes [28]. Fur-
thermore, the current AJCC staging system incorporates
primary tumor mitotic rate as a prognostic factor [29], but
SEER does not record this at present. It is possible that
differing mitotic rates between the two eras could have
contributed to MSS differences. Similarly, it is not possible
to make a perfect multivariate model. It is possible—
indeed likely—that additional factors, some as yet
unidentiﬁed, could have contributed to the MSS differences
noted in our study. As indicated previously, some data
ﬁelds are incomplete in the SEER database. In the spirit of
full disclosure, we listed those variables for which data
were unknown and included the unknowns in the multi-
variate analyses.
SEER data are beneﬁcial in several respects. Population-
based data are more readily generalized than single insti-
tution studies, which are subject to referral bias. Our study
represents a cross section of outcomes at university health
centers, rural community hospitals, and regional cancer
centers.
Over nearly two decades, melanoma-speciﬁc survival,
but not overall survival, has improved for AJCC stage III
melanoma patients. Stage migration is likely responsible
for any improvement in MSS among patients in the most
recently diagnosed era, although the increase in use of
biologic agents such as interferon alpha may also play a
role. New treatments for the management of stage III
melanoma are needed, and patients should be encouraged
to enter clinical trials.
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